Vemurafenib and cobimetinib was associated with a nonsignificantly higher incidence of adverse events of grade 3 or higher , as compared with vemurafenib and placebo ( 65 % vs. 59 % ) , and there was no significant difference in the rate of study-drug discontinuation .